Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where Are We Going?

Author(s): Renata Virgínia Cavalcanti Santos, Wanessa Layssa Batista de Sena, Flaviana Alves dos Santos, Antônio Felix da Silva Filho, Marina Galdino da Rocha Pitta, Maira Galdino da Rocha Pitta, Moacyr Barreto de Melo Rego, Michelly Cristiny Pereira*.

Journal Name: Current Drug Targets

Volume 20 , Issue 6 , 2019

Become EABM
Become Reviewer


One of the greatest challenges of cancer therapeutics nowadays is to find selective targets successfully. Prostate apoptosis response-4 (Par-4) is a selective tumor suppressor protein with an interesting therapeutic potential due to its specificity on inducing apoptosis in cancer cells. Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance. Efforts to increase Par-4 expression levels have been studied, including its use as a therapeutic protein by transfection with adenoviral vectors or plasmids. However, gene therapy is very complex and still presents many hurdles to be overcome. We decided to review molecules and drugs with the capacity to upregulate Par-4 and, thereby, be an alternative to reach this druggable target. In addition, Par-4 localization and function are reviewed in some cancers, clarifying how it can be used as a therapeutic target.

Keywords: Prostate apoptosis response-4, therapeutic innovation, tumor suppressor protein.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [635 - 654]
Pages: 20
DOI: 10.2174/1389450120666181126122440
Price: $95

Article Metrics

PDF: 9